SFCE (01165) receives additional resumption guidance from the Stock Exchange
SFCE (01165) announced that on November 2, 2026, the Company received a letter from the Stock Exchange (the Letter), which set out the following additional guidance for the resumption of trading in the Company's shares on the Stock Exchange:
SFCE (01165) announced that on November 2, 2026, the Company received a letter from the Stock Exchange (the Letter), which set out the following additional guidance for the resumption of trading in the Company's shares on the Stock Exchange:
- Re-comply with Rules 3.10(1), 3.10(2), 3.10A, 3.21, 3.25, 3.27A and 13.92(2) of the Listing Rules.
Related Articles
KPA-BM HLDGS (02663) changes controlling shareholder, receives a general offer at a discount of approximately 13.8%, trading resumes on November 5.
MICOT PHARMA-B (02335) received the first project funding under the National Science and Technology Major Project and obtained ethics approval from the lead site for the Phase III clinical trial of MT200605.
SKYFAME REALTY (00059) and the joint and several provisional liquidators entered into a restructuring agreement with Lion Wealth.
KPA-BM HLDGS (02663) changes controlling shareholder, receives a general offer at a discount of approximately 13.8%, trading resumes on November 5.
MICOT PHARMA-B (02335) received the first project funding under the National Science and Technology Major Project and obtained ethics approval from the lead site for the Phase III clinical trial of MT200605.
SKYFAME REALTY (00059) and the joint and several provisional liquidators entered into a restructuring agreement with Lion Wealth.
